Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $164.6 million.

  • Abivax's Total Liabilities changed N/A to $164.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.6 million, marking a year-over-year change of. This contributed to the annual value of $168.7 million for FY2024, which is 2546.75% up from last year.
  • According to the latest figures from Q3 2025, Abivax's Total Liabilities is $164.6 million.
  • In the past 5 years, Abivax's Total Liabilities ranged from a high of $190.1 million in Q2 2025 and a low of $66.6 million during Q4 2022
  • For the 5-year period, Abivax's Total Liabilities averaged around $146.0 million, with its median value being $166.6 million (2024).
  • As far as peak fluctuations go, Abivax's Total Liabilities plummeted by 2736.4% in 2022, and later surged by 10077.42% in 2023.
  • Quarter analysis of 5 years shows Abivax's Total Liabilities stood at $91.7 million in 2021, then decreased by 27.36% to $66.6 million in 2022, then soared by 100.77% to $133.7 million in 2023, then rose by 26.14% to $168.7 million in 2024, then fell by 2.39% to $164.6 million in 2025.
  • Its last three reported values are $164.6 million in Q3 2025, $190.1 million for Q2 2025, and $182.5 million during Q1 2025.